Strategies to treat Zika virus (ZIKV) infection in dengue virus
(DENV)-endemic areas are urgently needed. Here we show that a DENV-specific antibody against the E-dimer epitope (EDE) potently cross-neutralizes ZIKV and provides robust therapeutic efficacy as well as prophylactic efficacy against ZIKV in rhesus monkeys. Viral escape was not detected, suggesting a relatively high bar to escape. These data demonstrate the potential for antibody-based therapy and prevention of ZIKV.
Zika virus (ZIKV) has been associated with fetal microcephaly and other congenital abnormalities as well as Guillain-Barre syndrome 1, 2 . Our laboratory and others have shown that ZIKV-specific neutralizing antibodies correlate with vaccine protection in both mice and monkeys [3] [4] [5] [6] as well as with rapid control of viremia following infection in monkeys 7 . Several groups have also demonstrated therapeutic efficacy of ZIKV-specific monoclonal antibodies in immunosuppressed mice [8] [9] [10] [11] , and a cocktail of three ZIKV-specific monoclonal antibodies that targeted domain III was shown to prevent ZIKV infection in nonhuman primates 12 . In the present study, we assessed the therapeutic and prophylactic efficacy of a potent ZIKV-specific antibody in rhesus monkeys.
Substantial humoral cross-reactivity exists between DENV and ZIKV, and DENV-specific antibodies have been associated with antibody-dependent enhancement of ZIKV infection in vitro and in certain mouse models [13] [14] [15] . We previously reported that DENV E-dimer epitope (EDE)-specific monoclonal antibodies bind a quaternary epitope formed at the interface of head-to-tail E-dimers and efficiently cross-neutralize ZIKV [15] [16] [17] . EDE-specific monoclonal antibodies poorly bind to monomeric E-proteins but efficiently bind to stable E-dimers 18 . These antibodies can be subdivided into two groups, EDE1 and EDE2, according to their insensitivity or sensitivity, respectively, to removal of N-linked glycan at position 153. EDE1 monoclonal antibodies typically exhibit greater potency 15, 17 . Moreover, the EDE1-specific monoclonal antibody B10 has been shown to prevent and treat ZIKV infection in mice 8 . We evaluated 33 EDE1-specific antibodies isolated from patients infected with DENV 17 and found that B10 was the most potent in neutralizing a French Polynesian ZIKV strain (ZIKV-PF13; Fig. 1a ). B10 neutralized ZIKV-PF13 (50% neutralization titer (NT 50 ) of 0.016 ± 0.001 nM; NT 90 of 0.100 ± 0.009 nM (mean ± s.e.m.)) even more potently than DENV-1, DENV-2, and DENV-3 but showed poor neutralization of DENV4 (Fig. 1b) .
To confirm the antiviral activity of B10 against ZIKV in vivo, we performed a titration study in immunocompetent Balb/c mice. Groups of Balb/c mice (n = 5 mice per group) received a single infusion of 6.25, 3.12, 1.56, 0.78, 0.39, 0.19, 0.097, 0.048, or 0 μ g B10 and were subsequently challenged with 10 5 viral particles (VP) (10 2 plaque-forming units (PFU)) of ZIKV-BR via the intravenous route 4 ( Supplementary Fig. 1 ). In naive mice, ZIKV-BR infection led to peak viral loads of 5.24-6.18 log RNA copies per ml, similar to previous findings with this challenge stock 4 . B10 doses as low as 3.12 μ g, corresponding to serum levels of 0.5-0.9 μ g/ml (3-6 nM), resulted in complete protection against ZIKV-BR challenge in mice ( Supplementary Fig. 1 ). Subprotective B10 doses of 0.19-1.56 μ g resulted in partial protection of a subset of mice and attenuation of viral loads in infected animals. These data confirm B10 potency against ZIKV challenge in mice.
We next evaluated the therapeutic and prophylactic efficacy of B10 in rhesus monkeys (Macaca mulatta). Sixteen monkeys received the following antibodies by intravenous infusion either before or after challenge with the Brazil/ZKV2015 strain (ZIKV-BR) (n = 4 monkeys per group): (i) 10 mg per kg body weight (mg/kg) B10 on day -1, (ii) 10 mg/kg isotype matched control antibody (PGT121) 19, 20 on day -1, (iii) 10 mg/kg B10 on day + 2, or (iv) 10 mg/ kg isotype matched control antibody (PGT121) on day + 2. We selected this antibody dose on the basis of our previous experience with therapeutic HIV-1-specific antibody studies in SHIV-infected rhesus monkeys 19, 20 . Antibody pharmacokinetics was monitored using ELISA, and peak B10 levels were 78-306 μ g/ml (0.5-2 μ M) on the day after infusion (Fig. 1c) .
On day 0, all monkeys were challenged via the subcutaneous route with 10 6 VP (10 3 PFU) of ZIKV-BR, and viral loads were quantitated using RT-PCR 3, 7 . Animals that received the isotype matched sham control antibody either before or after ZIKV-BR challenge exhibited approximately 7 d of viremia with median peak viral loads of 6.40 (range, 5.31-6.60) log RNA copies per ml on day 3-5 following challenge (Fig. 2a) , consistent with our previous studies using this ZIKV-BR challenge stock in rhesus monkeys 3, 7 . Administration of B10 on day -1 before challenge resulted in complete protection, as evidenced by no detectable plasma viremia at any time point (P = 0.02 comparing infection of B10 group versus controls; Fisher's exact test). Administration of B10 on day + 2 after challenge, which was during the exponential rise of plasma viremia, resulted in an abrupt termination of viral replication and rapid clearance of virus We observed prolonged ZIKV-BR shedding in cerebrospinal fluid (CSF), lymph nodes (LN), and colorectal (CR) biopsies from sham-treated controls (Fig. 2b,c and Supplementary Fig. 2 ), consistent with our previous observations 7 . Monkeys that received B10 on day -1 before challenge had no detectable viral load in these tissues, in accordance with complete protection against infection. Moreover, these animals had no detectable cellular immune responses following ZIKV-BR challenge, as measured by interferon-γ (IFN-γ ) ELISPOT assays to ZIKV envelope protein (Env), nonstructural protein 1 (NS1), capsid protein (Cap), and premembrane (prM) peptide pools ( Supplementary Fig. 3 ). Monkeys that received B10 on day + 2 after challenge also showed a substantial reduction of viral load in tissues. However, ZIKV-BR was still detected in CSF of 2 of 4 monkeys on day 7 and in CSF of 1 of 4 monkeys on day 14. In this animal (12-083), the peak B10 level in CSF was 1 μ g/ml (0.5% of plasma levels). The prM-Env sequence from the virus in CSF on day 14 was identical to that of the ZIKV-BR challenge stock ( Supplementary Fig. 4) , suggesting that the virus did not specifically escape from B10. These data demonstrate that therapeutic B10 administration in monkeys acutely infected with ZIKV-BR rapidly controlled virus replication in the periphery within 24 h but incompletely cleared virus from immunoprivileged sites, likely as a result of reduced antibody penetration into these anatomic compartments.
To further evaluate the capacity of ZIKV to escape EDE1-specific monoclonal antibodies, we incubated ZIKV with escalating concentrations of the B10 or C8 antibodies 15, 16 in vitro at 0.002, 0.015, and 0.070 μ g/ml (corresponding to 50% focus reduction neutralization test (FRNT 50 ), FRNT 90 , and FRNT 99 ) for two, three, and five passages, respectively. After ten passages, parental and passaged viruses were analyzed for resistance to neutralization using FRNT assays. We did not observe viral escape under these conditions ( Supplementary Fig. 5 ), suggesting a relatively high bar to resistance. These findings are consistent with the observed therapeutic and prophylactic efficacy with B10 in rhesus monkeys even when delivered as monotherapy (Fig. 2) . In contrast, a cocktail of three domain III-specific monoclonal antibodies was required to prevent ZIKV infection in nonhuman primates 12 .
Our data demonstrate that a DENV EDE1-specific monoclonal antibody has potent cross-reactive neutralizing activity against ZIKV and provides robust therapeutic as well as prophylactic efficacy against ZIKV infection in rhesus monkeys. On the basis of the rapid clearance of plasma virus by 24 h after B10 infusion, we speculate that this antibody functions therapeutically by opsonization of virus followed by clearance. Previous studies have evaluated ZIKV-specific monoclonal antibodies in therapeutic studies in immunosuppressed mouse models [8] [9] [10] [11] . Our data extend these prior studies by demonstrating the therapeutic and prophylactic efficacy of a ZIKV-specific antibody in nonhuman primates. These findings encourage clinical development of ZIKV-specific monoclonal antibodies for both therapy and prevention.
The potency of B10 and the apparent relatively high bar to escape raise the possibility of antibody monotherapy, which would be logistically far simpler than the development of antibody cocktails 12 or bispecific antibodies 9 . The structure of B10 remains to be determined, but the related cross-reactive DENV-ZIKV EDE1-specific monoclonal antibody C8 binds a conserved quaternary site at the interface between the two Env subunits in the dimer at the interaction site of prM 16 , which may explain its high bar to escape. A potential challenge for any antibody-based ZIKV therapeutic strategy will likely involve persistent virus in immunoprivileged sites, as the virus may be quickly seeded in these sites within the first few days of infection. Such sites include the central nervous system, LN, and placental and fetal tissues. We previously reported that ZIKV persists in CSF, LN, and CR mucosa in monkeys for substantial periods of time after viremia resolves, and viral persistence at these sites correlates with activation of mTOR and proinflammatory signaling pathways 7 . We show here that B10 poorly penetrates into the CSF and thus may not fully clear CSF virus that was seeded before antibody administration.
A unique aspect of B10 is that it was derived from a DENVinfected individual before the ZIKV epidemic. Certain DENVspecific antibodies have been shown to enhance ZIKV replication in vitro and in mice [13] [14] [15] , although the relevance of these observations for humans remains to be determined. In our experiments, subneutralizing doses of B10 did not result in enhanced ZIKV replication in mice (Supplementary Fig. 1) . Nevertheless, the possibility of antibody-dependent enhancement with a cross-reactive DENV-ZIKV-specific antibody requires further investigation, and if necessary, mutations inactivating the fragment crystallizable region could be incorporated 8 . Our data also raise the possibility of developing antibody therapeutics targeting both flaviviruses in endemic areas.
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Sample size
For the NHP study, sample sizes of N=4/group were selected as standard for NHP studies to detect large differences between treatment and control arms. For the mouse studies, sample sizes of N=5/group were selected based on our prior experience of variability for this model system.
Data exclusions No data was excluded.
Replication
Mouse experiments were repeated twice. All attempts at replication were successful. Viral loads in the NHP study were done by qualified assays with multiple measures per animal.
Randomization Animals were randomly allocated to groups.
Blinding
Virologic and immunologic data was generated blinded.
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Validation
The B10 antibody was validated against known standards by functional neutralization activity against DENV and ZIKV, as depicted in Figure 1 .
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